These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18715920)

  • 21. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase.
    Chen Q; Cheng X; Wei D; Xu Q
    Interdiscip Sci; 2015 Mar; 7(1):36-42. PubMed ID: 25519157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.
    Myers RE; Pillay D
    J Virol; 2008 Sep; 82(18):9228-35. PubMed ID: 18596095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility.
    Varghese V; Pinsky BA; Smith DS; Klein D; Shafer RW
    AIDS Res Hum Retroviruses; 2016 Jul; 32(7):702-4. PubMed ID: 27009474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
    Andreatta KN; Miller MD; White KL
    Antimicrob Agents Chemother; 2016 Feb; 60(2):757-65. PubMed ID: 26574015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
    Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
    Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of novel HIV integrase inhibitors and the problem of drug resistance.
    Wainberg MA; Mesplède T; Quashie PK
    Curr Opin Virol; 2012 Oct; 2(5):656-62. PubMed ID: 22989757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
    Jones GS; Yu F; Zeynalzadegan A; Hesselgesser J; Chen X; Chen J; Jin H; Kim CU; Wright M; Geleziunas R; Tsiang M
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1194-203. PubMed ID: 19104010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013.
    Zoufaly A; Kraft C; Schmidbauer C; Puchhammer-Stoeckl E
    Infection; 2017 Apr; 45(2):165-170. PubMed ID: 27530391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
    Van Baelen K; Van Eygen V; Rondelez E; Stuyver LJ
    AIDS; 2008 Sep; 22(14):1877-80. PubMed ID: 18753927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
    Yotsumoto M; Hachiya A; Ichiki A; Amano K; Kinai E
    AIDS; 2020 Nov; 34(14):2155-2157. PubMed ID: 32932342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.